Big Pharma R&D legend Paul Stoffels is trading his J&J title for the CEO role at one of the most deeply troubled biotechs in the industry
After 20 years working at the pinnacle of Big Pharma R&D, taking lead roles in J&J’s pipeline revamp and a quickly developed, one-shot Covid vaccine that is being sold around the world, it turns out the legendary Paul Stoffels has at least one more chapter ahead in his career.
And this one will be the biggest challenge the 59-year-old has faced yet.
After the market closed Wednesday, the longtime scientist was officially named as the new CEO of Galapagos, a troubled biotech trying to undergo a facelift in the wake of a disastrous alliance with Gilead that ended with the implosion of a drug program billed as one of the industry’s next big blockbuster stories.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.